Playing It Safe? Hahn's Biosimilar View

 
• By Derrick Gingery

US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing today
US FDA Commissioner nominee Stephen Hahn awaits the start of his Senate confirmation hearing on 20 November, where he responded to questions about biosimilars, vaping and other issues. • Source: Derrick Gingery

More from Biosimilars

More from Biosimilars & Generics